Business
AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate – The Motley Fool Australia
AstraZeneca PLC (LON: AZN) has revised its COVID-19 vaccine efficacy rating after concluding a more extensive study previously done.
Home / Coronavirus News / AstraZeneca COVID-19 vaccine trial data results in revised efficacy rateThe Oxford-AstraZeneca PLC (LON: AZN) COVID-19 vaccine has travelled a bumpy road through its development and rollout. Marred with accusations of the vaccine causing blood clots, regulatory and government pressures have weighed on the drug developer and its acceptance.
According to the latest press release from AstraZeneca, the company has revised the vaccine’s efficacy from 79% to 76%, following…
-
Noosa News24 hours agoMitch Power Quick Shear event gets men talking about mental health
-
Noosa News18 hours agoNRL live updates: Newcastle Knights vs Melbourne Storm, St George Illawarra Dragons vs Sydney Roosters, North Queensland Cowboys vs Canterbury Bulldogs
-
Noosa News19 hours ago‘Shocked’ Labor calls in corruption watchdog over CFMEU report
-
Noosa News19 hours agoCreating space for cultural pride – Proctor